SCI论文全攻略审稿回复

《SCI论文全攻略审稿回复》由会员分享，可在线阅读，更多相关《SCI论文全攻略审稿回复（14页珍藏版）》请在装配图网上搜索。

1、SCI论文全攻略之审稿回复实例发布时间：2011-4-4Tags: SCI论文 附1：SCI扩展版和SCI核心版收录期刊的区别 SCI扩展版（以下简称SCIE）和SCI核心版（以下简称SCI）收录期刊还是有区别的，SCI期刊论文全部被SCI收录，SCIE期刊论文只是部分被SCI收录，这就是有的SCIE期刊一年有几百篇论文，却只有几十篇甚至十几篇论文被SCI收录的原因。具体到SCIE期刊上的一篇论文能否被SCI收录，还是要看美国ISI发布的报告，现在科技部信息研究所也公布这一报告，很多图书馆的SCI检索机构也可以查。 不过在国内，很多单位都把SCI期刊论文和SCIE期刊论文一视同仁，只要发表在S

2、CI期刊或SCIE期刊上，该论文都当作SCI收录，这是管理者的无能抑或无为就不得而知了。但就我们单位而言（国内TOP10高校），这两者还是区别对待的，论文是否SCI收录还是看CISI的报告或SCI检索机构的证据。附2：如何回复SCI投稿审稿人意见(1) 1.所有问题必须逐条回答。2.尽量满足意见中需要补充的实验。3.满足不了的也不要回避，说明不能做的合理理由。4.审稿人推荐的文献一定要引用，并讨论透彻。以下是本人对审稿人意见的回复一例，仅供参考。续两点经验：1，最重要的是逐条回答，即使你答不了，也要老实交代；不要太狡猾，以至于耽误事；2，绝大部分实验是不要真追加的，除非你受到启发，而想改投另外

3、高档杂志-因为你既然已经写成文章，从逻辑上肯定是一个完整的 “story” 了。国外杂志要求补充实验的，我均以解释而过关。还因为：很少杂志编辑把你的修改稿再寄给当初审稿人的，除非审稿人特别请求。编辑不一定懂你的东西，他只是看到你认真修改，回答疑问了，也就接受了（当然高档杂志可能不是这样，我的经验只限定一般杂志（影响因子1-5）。我常用的回复格式01：Dear reviewer:I am very grateful to your comments for the manuscript. According with your advice, we amended the relevant pa

4、rt in manuscript. Some of your questions were answered below.1）2）.引用审稿人推荐的文献的确是很重要的，要想办法和自己的文章有机地结合起来。至于实验大部分都可以不用补做，关键是你要让审稿人明白你的文章的重点是什么，这个实验对你要强调的重点内容不是很必要，或者你现在所用的方法已经可以达到目的就行了。最后要注意，审稿人也会犯错误，不仅仅是笔误也有专业知识上的错误，因为编辑找的审稿人未必是你这个领域的专家。只要自己是正确的就要坚持。在回复中委婉地表达一下你的意见，不过要注意商讨语气哦！我得回复格式02：Dear Professor xx

5、:Thank you very much for your letter dated xxx xx xxxx, and the referees reports. Based on your comment and request, we have made extensive modification on the original manuscript. Here, we attached revised manuscript. in the formats of both PDF and MS word, for your approval. A document answering e

6、very question from the referees was also summarized and enclosed. A revised manuscript. with the correction sections red marked was attached as the supplemental material and for easy check/editing purpose. Should you have any questions, please contact us without hesitate.然后再附上Q/A，基本上嘱条回答，写的越多越好（老师语）

7、。结果修改一次就接收了：）我的回复，请老外帮忙修改了。Dear Editor:Thank you for your kind letter of “.” on November *, 2005. We revised the manuscript. in accordance with the reviewers comments, and carefully proof-read the manuscript. to minimize typographical, grammatical, and bibliographical errors.Here below is our descri

8、ption on revision according to the reviewers comments. Part A (Reviewer 1). The reviewers comment: .The authors Answer: .2. The reviewers comment: .The authors Answer: .Part B(Reviewer 2)1. The reviewers comment: .The authors Answer: .2. The reviewers comment: .The authors Answer: .Many grammatical

9、or typographical errors have been revised.All the lines and pages indicated above are in the revised manuscript.Thank you and all the reviewers for the kind advice.Sincerely yours,*如何回复SCI投稿审稿人意见(2) 一个回复的例子(已接收)Major comments:1. The authors need to strengthen their results by including MMP secretion

10、, and tran-matrigel migration by a positive control progenitor cell population i.e. enriched human CD34 cells obtained from mobilized PBL, since this is a more clinically relevant source of CD34 cells which has also been shown to secrete both MMP-9 and MMP-2 (ref. 11). CD34 enriched cells from stead

11、y state peripheral blood which also secrete MMPs are also of interest.2. In fig1Cplease specify which cell line represents MMP-negative cells. This needs to be clarified, as well as a better explanation of the method of the protocol.3. The ELISA results are represented as fold increase compared to c

12、ontrol. Instead, we suggest that standards should be used and results should be presented as absolute concentrations and only then can these results be compared to those of the zymography.4. When discussing the results, the authors should distinguish clearly between spontaneous migration vs chemotac

13、tic migration.Furthermore, the high spontaneous migration obtained with cord blood CD34 cells should be compared to mobilized PBL CD34 enriched cells and discussed.5. The authors claim that the clonogenic assay was performed to determine the optimum concentration for inhibition of MMP activity by ph

14、enanthroline and anti MMP-9 mAb, however they should clarify that this assay can only determine the toxicity of the inhibitors and not their optimal inhibitory concentrations.Minor comments:1. There are many spelling and syntax errors, especially in the results and discussion, which need correction.

15、a. Of special importance, is the percent inhibition of migration,which is described as percent of migration. i.e. pg 7:Migration of CB CD34 was reduced to 73.3%? Instead should read Migration of CB CD34 was reduced by 73.3%?b. The degree symbol needs to be added to the numbers in Materials and metho

16、ds.2. It would be preferable to combine figure1Aand B, in order to confirm the reliability of fig. 1B by a positive control (HT1080).Answer to referee 1 comment:1. Mobilized peripheral blood is a more clinical source of CD34+ cells, so it is necessary to compare the MMP-9 secretion and trans-migrati

17、on ability of CB CD34+ cells with that of mobilized PB CD34+ cells. However, we couldnt obtain enough mobilized PB to separate PB CD34+ cells and determine the MMP-9 secretion and migration ability, so we couldnt complement the study on PB CD34+ cells in this paper. Results obtained by Janowska-Wiec

18、zorek et al found that mobilized CD34+ cells in peripheral blood express MMP-9. Furthermore, Domenechs study showed that MMP-9 secretion is involved in G-CSF induced HPC mobilization. Their conclusions have been added in the discussion. In our present study, our central conclusion from our data is t

19、hat freshly isolated CD34+ stem/progenitor cells obtained from CB produce MMP-9.2. MMP-9 negative cell used in fig1Cwas Jurkat cell. In zymographic analysis, MMP-9 was not detected in the medium conditioned by Jurkat cell. To exclude that the contaminating cells may play a role in the observed MMP-9

20、 production, we screened the media conditioned by different proportion of CB mononuclear cells with MMP-9 negative cells by zymography. This result may be confusion. Actually, only by detecting the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml (since the purities of CD34+ cell are more t

21、han 90%), it could exclude the MNC role. In the revised manuscript, we only detected MMP-9 activity and antigen level in the medium conditioned by 2X105 CB mononuclear cells (MNC)/ml. There is no MMP-9 secretion be detected in the medium conditioned by 2X105 CB MNC/ml. It excluded the possibility th

22、at the MMP-9 activity in CB CD34+ cells conditioned medium is due to the contamination by MNC.3.In this revised paper, we have detected the MMP-9 antigen levels by using commercial specific ELISA kits (R&D System, sensitivity, 0.156ng/ml). Recombinant MMP-9 from R&D System was used as a standard. Th

23、e results are expressed in the absolute concentration. The absolute concentration result has been added in the paper. As shown in Fig2, MMP-9 levels were detectable in both CB CD34+ cell conditioned medium and BM CD34+ cell conditioned medium. However, MMP-9 level was significantly higher in CB CD34

24、+ cell conditioned medium than in BM CD34+ cell conditioned medium (0.4060.133ng/ml versus 0.1950.023ng/ml). Although gelatinolytic activity was not detected in media conditioned by CD34+ cells from BM, sensitivity of ELISA favors the detection of MMP-9 antigen in the BM CD34+.4. In our study, to es

25、tablish the direct link between MMP-9 and CB CD34+ cells migration, we only determined the role of MMP-9 inspontaneous migration of CB CD34+ cells, but not in chemotactic migration. Actually, regulation of hematopoietic stem cell migration, homing and anchorage of repopulation cells to the bone marr

26、ow involves a complex interplay between adhesion molecules, chemokines, cytokines and proteolytic enzymes. Results obtained by the groups of Voermans reveal that not only the spontaneous migration but also the SDF-1 induced migration of CB CD34+ cells is greatly increased in comparison to CD34+ cell

27、s from BM and peripheral blood.5. CD34+ cells we obtained in each cord blood sample were very limited. It is not enough to screen the inhibitors concentrations to select the optimal inhibitory concentrations. In the blocking experiments, based on the concentrations used by others and the manufacture

28、rs recommendation, we then determined the inhibitors concentrations by excluding the toxicity of the inhibitors in that concentration, which was determined by clonogenic assay.Minor comments:1.The spelling and syntax errors have been checked and corrected.2.Since the results in figure1Aand B were ob

29、tained from two separated and parallel experiments, it is not fitness to combine two figures.这是我的一篇修稿回复，杂志是JBMR-A，影响因子3.652，已发表。供参考！Reply to the comments on JBMR-A-05-0172Comment:Reference #10 is missing from the Introduction but used much later in the manuscript. Should these be in order used in ma

30、nuscript?Reply:The missing reference has been added into the revised manuscript.Comment (continued):What is the sample size for all tests performed?Reply:The sample size for drug release and PCL degradation tests was 3.03.0 cm2, with a thickness of about0.1mmand a weight of about 40mg. This dada hav

31、e been added into the revised manuscript.Comment (continued):Figure 7. There is no scientific evidence presented in the TEM figure to convince this reviewer of sub-jets. This statement on Page 9 cannot be made without clear evidence during the jet formation/separation. Figure 7 is just a large fiber

32、 and small fiber fused together, no other conclusion than this can be made.Reply:Necessary change in the statements has been made in the revised manuscript. as well as in the referred figure accordingly.Comment (continued):Table 3: Need standard deviation for all values reported not just for a selec

33、t few.Equation after Table 3 not necessary. Just reference method used.Reply:Done accordingly.Comment (continued):Page 11: faster weight loss What was the sample size? Where is the statistical analysis of this data? This reviewer does not see a significant difference in any of the data presented, th

34、us weight loss would be considered equivalent.Reply:Although not too much difference was seen, the conclusion that “the GS/PCL membrane exhibited a relatively faster weight loss compared with the RT/PCL membrane” was indeed applicable through “one-way analysis of variance (ANOVA)” analysis. Followin

35、g the reviewers comment, a new sub-section has been added to the manuscript. to address the statistical analysis for the data.Comment (continued):Page 12: What is the sample size for release data? Looks like results based on a sample size of one? Need stand deviations on the data presented in Figure

36、 11. Why wasnt releaseperformed and compared for all electrospun conditions investigated otherwise?Reply:Three repeated tests were performed for each set of measurements and the resulting data were averaged. As stated in the revised manuscript, each sample had a square area of 33cm2 with a s

37、lightly different thickness.Standard deviations have been added to the data shown in Fig. 11.The present manuscript. aimed to show that medical drugs can be encapsulated in ultrafine fibers through a co-axial electrospinning process. The drug release data intended to show that the encapsulation was

38、successful. We did not consider any specific application in this preliminary paper, and in fact the two drugs were just chosen as model illustration. As such, there seemed not necessary to perform. release experiments for all of the membranes electrospun with different conditions (i.e. the core conc

39、entrations)Comment (continued):Table 3: Yangs or Youngs Modulus (page 10 says Youngs).Reply:Corrected accordingly.Comment (continued):Figure 11: What is the % release, not just concentration. Why just this small sample of release data? Where is the release data for the other conditions?Reply:Unfortu

40、nately, we did not measure the amount of the shell material in obtaining the composite nanofibers. Namely, the flow rate of the shell solution during the electrospinning was not accurately controlled using an injecting pump. Hence the % release was not applicable. Please refer to the previous reply

41、related to Page 12 and Figure 11 for the remaining comments.We acknowledge the reviewers comments and suggestions very much, which are valuable in improving the quality of our manuscript.附3：SCI生物医学英文论文发表成功经验 SCI生物医学英文论文发表成功经验共享系列一，（Clinical Chemistry）将自己近10年的科研工作中有关论文整理总结发表方面的一些信息贡献出来，与大家共享！如有时间，我拟将

42、一些已经发表的文章，按照撰写与发表的实际经历与过程，即通过案例分析每一个杂志的特色，审稿偏好，review意见及答复要点等逐一分析。可能包含的杂志系列有：nature methods，clinical chemistry，analytical chemistry，J. Clin. Immuno，Biomed. Microdev，Front. Biosci，Mol. Cell. Biochem，J. Expert，Rev. Proteomics，J biochemistry等。本章先讲解美国Clinical Chemistry杂志，一个临床化学界的王牌杂志，近年其影响因子逐年攀升，现为7.7分。

43、Clinical Chemistry由美国AACC每月出版，接受的文章包括与人体疾病相关的实验室研究，分析与分子诊断，仪器，资料处理，数据分析，临床研究等投稿。ISSN：0009-9147网络版ISSN：1530-8561【URL】http:/intl.clinchem.org/【镜像URL】http:/www.clinchem.org/【出版者】American Association for Clinical Chemistry (AACC)【收费情况】 免费，全文【内容简介】Clinical Chemistry is an international journal of laborat

44、ory medicine and molecular diagnostics.Clinical Chemistry - This highly respected and often-cited scientific journal is published monthly and contains peer-reviewed methodology, research papers and other articles relevant to clinical chemistry and related laboratory sciences. Its circulation is more

45、 than 15,000.David E. Bruns, MD, Editor, (Charlottesville Office)dbrunsclinchem.aacc.orgSandra Weaver, Senior Editorial Assistantsweaverclinchem.aacc.orgDonna Brandl, Editorial Assistantdbrandlclinchem.aacc.orgShane P. Cyr, Editorial Assistantscyrclinchem.aacc.orgMac Fancher, Publisher, (WashingtonO

46、ffice)mfancheraacc.orgMiriam Gonzalez, Publications Coordinatormgonzalezaacc.org【目录、摘要或全文上网等情况】Free TOC, 1965 -Free Abstract, 1975 -Free Fulltext, 1997 -1999Fulltext, 1997 -【杂志被索引的情况】Indexed in Chemical Abstracts.【备注】For faster access to Clinical Chemistry Online from these countries use this URL:ht

47、tp:/intl.clinchem.orgAustralia, Brazil, China, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Mexico,Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, The Netherlands, UK该杂志是由美国临床化学协会（American Association for Clinical Chemistry，AACC）主办的，于1948年成立，总部位于华盛顿，拥有

48、1万余会员。先在网站注册，登记，按照提示一步步提供文章名称，摘要，作者姓名，所属领域，关键词，主文，图表等等。转换为PDF后就可以提交，然后给你一个查询号，接着就是等待了。等了20多天，查阅状态看到了第一次回信：Home Author Area Reviewer Area Personal Info. ClinChem Home Sign Out Submit New Manuscript. Information for Authors Queue Summary Feedback Help FAQDecision LetterReturn to QueueTo:作者姓名（电子邮件）From

49、: clinchemedclinchem.aacc.orgSubject: Clinical Chemistry - Manuscript. DecisionCc:RE: Clinical Chemistry MS ID# CLINCHEM/2002/036332TITLE:Dear Dr. xxx:Your manuscript. has been examined by two expert reviewers. Please visit http:/submit.clinchem.org to view their comments. For the reasons detailed i

50、n these comments, we cannot accept this manuscript. for publication in Clinical Chemistry in this form. Also, your Reference 28 is not formatted properly. Our Information for Authors will offer assistance with journal style; it can be found athttp:/www.aacc.org/ccj/infoauth.stmWe would consider a re

51、vised version that takes these criticisms into account. If you should resubmit the paper I would also ask that you have several English speaking colleagues proof the paper for grammar and composition. Additionally, be sure to provide a detailed point-by-point response to the comments of the reviewer

52、s. Failure to do so will delay consideration of the revised manuscript.Prior to publication we require copyright releases signed by all authors. Our Authors Assurances and Assignment of Copyright form. can be downloaded from http:/www.aacc.org/ccj/auth_assure02.pdf. Please note that all authors must

53、 sign both sections of the form. (a signature on the lower section means that all conflicts of interest have been disclosed even if there are none). Send the completed form. to us by FAX (434-979-7599).Sincerely,Dr. xxx nesleyAssociate EditorP.S. You will find your revised manuscript. can be uploade

54、d in your Submit a Revision queue at http:/submit.clinchem.org. Please do not begin the submission of your revised manuscript. until you are ready to submit the entire manuscript. A checklist regarding requirements for submission can be found athttp:/www.aacc.org/ccj/manuscript_check02.pdf. Figures

55、must be uploaded as Image Files in .tif or .eps files at 600 DPI. Alternatively, you may use PowerPoint software for figures but fonts must be embedded and only one image per slide, one slide per file. When uploading the revised version, please be sure to include in the Response to Reviews field a p

56、oint-by-point list of all changes made, or your rebuttal, in response to each of the reviewers?suggestions.P.P.S. Please note that if your manuscript. has color figures, the authors are expected to bear the cost of printing them, except in the case of invited papers. The charges for these figures ar

57、e $1500 for the first color figure or part of a figure, and $500 for each additional color figure or part of a figure. Authors will be billed for color publication costs unless they request that their figures be printed in black and white.该杂志一般为2个审稿人，审稿过程也较严格，都是本领域的大牛。后来我还有幸在一次会议上认识到一个当年的审稿人，但不知道是1还

58、是2，呵呵！一般总是先鼓励一段话，不写了。下面问题就来了，共12个，有些很好回答，一句话就可以解释清楚，有些就比较麻烦。还是举例说明把-1）实验的有效性和深度（at least for a few substances of major importancedetection limits, cut-off values and specificity should have beenstudied. Also the description of the assay principle is not quiteclear）没办法，只有一条路，补充相关实验，然后再投。2）语言问题（The En

59、glish text would have to be substantially improved）虽然这是一个美国杂志，但对语言的要求一点都不弱，投之前还是忽略了，没办法，慢慢修改。3）核心的技术问题（A cut-off value is given for MOL but the dimension is missing. In the discussion various anecdotic reports are given for which no data are presented under results.） 重新验证讨论。 本来认为很快就可以接受了，没想到却又等了一个半月

60、（中间发过一次信件询问）才收到回信。原来除了上次2个评委，这次又增加了一个独立审稿人。原文如下：Your revised manuscript. has been examined by the original two reviewers, plus a recommended third reviewer with special expertise in this area. Please visit http:/submit.clinchem.org to retrieve their comments. The three reviewers find merit in the wo

61、rk, but have numerous constructive suggestions（别害怕，其实就是几个小问题）. Please consider these suggestions carefully and prepare an improved version that addresses these concerns. I have also noted that there are several color figures included in the paper, which seem to be useful only in color. Please be awa

62、re that (should your paper be accepted for publication) authors are expected to pay the costs for publication of color figures. The charge for the first color figure is $1500; subsequent figures, or parts of figures, are $500 each. Of course, if you wish to submit alternate figures in black and whit

63、e (or grayscale), you may do so.Sincerely,Dr. xxxAssociate EditorP.S. You will find your revised manuscript. can be uploaded in your Submit a Revision queue at http:/submit.clinchem.org. A checklist of requirements for submission can be found at http:/www.aacc.org/ccj/manuscript_check02.pdf. When up

64、loading the revised version, please be sure to include in the Response to Reviews field a point-by-point list of all changes made, or your rebuttal, in response to each of the reviewer suggestions. Also, please submit copyright releases for all authors. Our Authors Assurances and Assignment of Copyright form. can be downloaded from http:/www.aacc.org/ccj/auth_assure02.pdf. Please note that all authors must sign both sections of the form. Send the completed form. to us by FAX (434-979-7599).P.P.S. For figures, please su